13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001778253
Total reported value
$928.2M
$928.2M
100 檔
29.8%
According to the latest 13F quarterly dataset, Ikarian Capital, LLC managed an equity portfolio of $928.2M at the end of Q1 2024, spanning 100 distinct U.S. exchange-listed positions.
During Q1 2024, Ikarian Capital, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 9.27% | — | -7.23% | |
| 2 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 7.28% | -3.19% | +27.27% | |
| 3 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 5.06% | — | +15.18% | |
| 4 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 4.89% | — | +22.10% | |
| 5 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 3.81% | — | -35.65% | |
| 6 | CORT | Corcept Therapeutics Inc | Stock-Healthcare | 3.52% | — | +134.80% | |
| 7 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 3.23% | +0.03% | +31.00% | |
| 8 | IRON | Disc Medicine Inc | Stock-Other | 3.22% | +0.21% | NEW | |
| 9 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 3.03% | -0.94% | EXIT | |
| 10 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 2.41% | — | +185.49% | |
| 11 | AZNN | Astrazeneca Plc-spons Adr | Stock-Other | 2.30% | — | — | |
| 12 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 2.28% | -0.86% | +41.91% | |
| 13 | EYPT | Eyepoint Inc | Stock-Other | 1.96% | +0.36% | -16.94% | |
| 14 | BMEA | Biomea Fusion Inc | Stock-Other | 1.94% | — | -7.59% | |
| 15 | CYTK | Cytokinetics Inc | Stock-Healthcare | 1.88% | -6.65% | EXIT | |
| 16 | AMGN | Amgen Inc | Stock-Healthcare | 1.87% | — | +71.43% | |
| 17 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 1.80% | — | — | |
| 18 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 1.80% | +0.01% | — | |
| 19 | NVLSEUR | Alpine Immune Sciences Inc | Stock-Other | 1.58% | — | -25.22% | |
| 20 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 1.50% | — | — | |
| 21 | INSM | Insmed Inc | Stock-Healthcare | 1.40% | -0.06% | EXIT | |
| 22 | MGNX | Macrogenics Inc | Stock-Other | 1.36% | +0.02% | — | |
| 23 | BHVN | Biohaven Ltd. | Stock-Other | 1.34% | +0.92% | — | |
| 24 | SRRK | Scholar Rock Holding CORP | Stock-Other | 1.27% | — | — | |
| 25 | PRAX | Praxis Precision Medicines I | Stock-Other | 1.27% | +1.51% | -4.91% | |
| 26 | ✓ | Stock-Other | 1.19% | — | — | ||
| 27 | LNTH | Lantheus Holdings Inc | Stock-Healthcare | 1.16% | — | -40.35% | |
| 28 | ✓ | Acelyrin Inc | Stock-Other | 1.16% | — | -32.80% | |
| 29 | ANNX | Annexon Inc | Stock-Other | 1.10% | — | -46.98% | |
| 30 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 1.07% | — | +85.27% | |
| 31 | MRNS* | Marinus Pharmaceuticals Inc | Stock-Other | 1.04% | — | +41.18% | |
| 32 | ARE | Alexandria Real Estate Equit | Stock-Real Estate | 1.04% | — | — | |
| 33 | IMVT | Immunovant Inc | Stock-Other | 0.98% | — | -60.37% | |
| 34 | CPRX | Catalyst Pharmaceuticals Inc | Stock-Healthcare | 0.91% | — | +2.48% | |
| 35 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 0.88% | — | -23.77% | |
| 36 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 0.87% | — | -26.72% | |
| 37 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 0.87% | — | -21.24% | |
| 38 | NUVL | Nuvalent Inc-a | Stock-Other | 0.84% | -0.20% | EXIT | |
| 39 | PYXS | Pyxis Oncology Inc | Stock-Other | 0.78% | — | — | |
| 40 | ABEO | Abeona Therapeutics Inc | Stock-Other | 0.76% | — | +59.35% | |
| 41 | TRML | Tourmaline Bio Inc | Stock-Other | 0.72% | — | — | |
| 42 | LYRAGBP | Lyra Therapeutics Inc | Stock-Other | 0.72% | — | -15.75% | |
| 43 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 0.66% | — | +2.13% | |
| 44 | ANVS | Annovis Bio | Stock-Other | 0.65% | — | +14661.76% | |
| 45 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 0.64% | — | — | |
| 46 | CYBNEUR | Cybin Inc | Stock-Other | 0.63% | — | — | |
| 47 | CRVO | Cervomed Inc | Stock-Other | 0.61% | — | — | |
| 48 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.58% | — | +742.74% | |
| 49 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.51% | — | -30.44% | |
| 50 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 0.49% | +0.23% | NEW |
According to official SEC Form 13F filings, Ikarian Capital, LLC reported a total U.S. public equity portfolio value of $928.2M across 100 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including KRYS, XBI, ALNY) accounted for 29.8% of total reported equity market value during Q1 2024.
During Q1 2024, Ikarian Capital, LLC's top holdings by market value included KRYS (9.3%)、XBI (7.3%)、ALNY (5.1%). The largest single position, KRYS, represented 9.3% of total portfolio value.
In Q1 2024, Ikarian Capital, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.